Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 10 , Pages 1375-1379 , October 2007

Pharmacological Management of Bipolar Disorder in a Youth With Diabetes

,Accepted 30 May 2007.

REFERENCES 

  1. Bergman RN , Ader M . Atypical antipsychotics and glucose homeostasis . J Clin Psychiatr . 2005;66:504–514
  2. Bowden CL , Calabrese JR , Ketter TA , Sachs GS , White RL , Thompson TR . Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder . Am J Psychiatry . 2006;163:1199–1201
  3. Correll CU , Carlson HE . Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents . J Am Acad Child Adolesc Psychiatry . 2006;45:771–791
  4. Correll CU , Leucht S , Kane JM . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies . Am J Psychiatry . 2004;161:414–425
  5. Cramer JA , Rosenheck R . Compliance with medication regimens for mental and physical disorders . Psychiatr Serv . 1998;49:196–201
  6. DelBello MP , Kowatch RA . Pharmacological interventions for bipolar youth: developmental considerations . Dev Psychopathol . 2006;18:1231–1246
  7. Findling RL , McNamara NK , Youngstrom EA , et al.   Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder . J Am Acad Child Adolesc Psychiatry . 2005;44:409–417
  8. Joffe H , Cohen LS , Suppes T , et al.   Longitudinal follow-up of reproductive and metabolic features of valrproate-associated polycystic ovarian syndrome features: a preliminary report . Biol Psychiatry . 2006;60:1378–1381
  9. Kowatch RA , Fristad M , Birmaher B , et al.   Treatment guidelines for children and adolescents with bipolar disorder . J Am Acad Child Adolesc Psychiatry . 2005;44:213–235
  10. McClellan J , Kowatch R , Findling RL , et al.   Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder . J Am Acad Child Adolesc Psychiatry . 2007;46:107–125
  11. Pappadopulos E , Macintyre Ii JC , Crismon ML , et al.   Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II . J Am Acad Child Adolesc Psychiatry . 2003;42:145–161
  12. Ratzoni G , Gothelf D , Brand-Gothelf A , et al.   Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study . J Am Acad Child Adolesc Psychiatry . 2002;41:337–343
  13. Richardson MA , Haugland G , Craig TJ . Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients . Am J Psychiatry . 1991;148:1322–1328
  14. Scherk H , Pajonk FG , Leucht S . Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials . Arch Gen Psychiatry . 2007;64:442–455
  15. Schur SB , Sikich L , Findling RL , et al.   Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review . J Am Acad Child Adolesc Psychiatry . 2003;42:132–144
  16. Urakami T , Morimoto S , Owada M , Harada K . Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus . Pediatr Int . 2005;47:430–433
  17. Zarate CA , Tohen M . Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients . Am J Psychiatry . 2004;161:169–171

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. DelBello has served as a consultant to or a speaker for or received research funding from AstraZeneca, Abbott, Eli Lilly, Pfizer, Shire, and Janssen. Dr. Correll has been a consultant to AstraZeneca, Bristol-Myers Squibb/Otsuka, Eli Lilly, Solvay, and Intracellular Therapies; an advisor to Bristol-Myers Squibb/Otsuka and Eli Lilly; and a lecturer for AstraZeneca and Bristol-Myers Squibb/Otsuka. Dr.G. Carlson has received research grants from Janssen, Otsuka, Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly, and has been an advisor to Janssen, Otsuka, Eli Lilly, and Shire. Dr. H. Carlson has served as a consultant to Otsuka. Dr. Kratochvil receives grant support from Eli Lilly, McNeil, Shire, Abbott, and Cephalon; is a consultant to Eli Lilly, Cephalon, AstraZeneca, Abbott, and Pfizer; and is a member of the Eli Lilly speakers' bureau. Dr. Kratochvil receives study drug for an NIMH-funded study from Eli Lilly.

PII: S0890-8567(09)61857-8

doi: 10.1097/chi.0b013e31813c69c9

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 10 , Pages 1375-1379 , October 2007

Article Tools